{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:19:27Z","timestamp":1778545167963,"version":"3.51.4"},"reference-count":84,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009983","name":"CMMC","doi-asserted-by":"publisher","award":["A05"],"award-info":[{"award-number":["A05"]}],"id":[{"id":"10.13039\/501100009983","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["455784452"],"award-info":[{"award-number":["455784452"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["A06"],"award-info":[{"award-number":["A06"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.hoc.2025.06.001","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T03:59:05Z","timestamp":1753156745000},"page":"965-979","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Understanding and Targeting BCL2-inhibitor Resistance in Chronic Lymphocytic Leukemia"],"prefix":"10.1016","volume":"39","author":[{"given":"Alexander F.","family":"vom Stein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas P.","family":"Frenzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5381","key":"10.1016\/j.hoc.2025.06.001_bib1","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1126\/science.281.5381.1322","article-title":"The Bcl-2 protein family: arbiters of cell survival","volume":"281","author":"Adams","year":"1998","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.hoc.2025.06.001_bib2","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1182\/blood.V82.6.1820.1820","article-title":"bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia","volume":"82","author":"Hanada","year":"1993","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2025.06.001_bib3","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1182\/blood.V79.11.2981.2981","article-title":"Growth- and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukemia cells","volume":"79","author":"Schena","year":"1992","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2025.06.001_bib4","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrc2764","article-title":"From pathogenesis to treatment of chronic lymphocytic leukaemia","volume":"10","author":"Zenz","year":"2010","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1016\/j.hoc.2025.06.001_bib5","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.hoc.2025.06.001_bib6","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","article-title":"Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease","volume":"30","author":"Roberts","year":"2012","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.hoc.2025.06.001_bib7","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1182\/blood-2017-01-763003","article-title":"Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax","volume":"129","author":"Anderson","year":"2017","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.hoc.2025.06.001_bib8","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.hoc.2025.06.001_bib9","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1470-2045(17)30012-8","article-title":"Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2025.06.001_bib10","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","article-title":"Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia","volume":"9","author":"Blombery","year":"2019","journal-title":"Cancer Discov"},{"issue":"9","key":"10.1016\/j.hoc.2025.06.001_bib11","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.3324\/haematol.2019.222588","article-title":"Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia","volume":"104","author":"Tausch","year":"2019","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.hoc.2025.06.001_bib12","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.cell.2012.12.031","article-title":"Bax crystal structures reveal how BH3 domains activate Bax and nucleate its oligomerization to induce apoptosis","volume":"152","author":"Czabotar","year":"2013","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.hoc.2025.06.001_bib13","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a036319","article-title":"BAX, BAK, and BOK: a coming of age for the BCL-2 family effector proteins","volume":"12","author":"Moldoveanu","year":"2020","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"2","key":"10.1016\/j.hoc.2025.06.001_bib14","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S1097-2765(03)00051-0","article-title":"A unified model for apical caspase activation","volume":"11","author":"Boatright","year":"2003","journal-title":"Mol Cell"},{"issue":"8","key":"10.1016\/j.hoc.2025.06.001_bib15","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1038\/cdd.2017.44","article-title":"Caspases and their substrates","volume":"24","author":"Julien","year":"2017","journal-title":"Cell Death Differ"},{"issue":"4","key":"10.1016\/j.hoc.2025.06.001_bib16","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0092-8674(00)80434-1","article-title":"Cytochrome c and dATP-dependent formation of Apaf-1\/caspase-9 complex initiates an apoptotic protease cascade","volume":"91","author":"Li","year":"1997","journal-title":"Cell"},{"issue":"25","key":"10.1016\/j.hoc.2025.06.001_bib17","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2016-01-688796","article-title":"The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism","volume":"127","author":"Anderson","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2025.06.001_bib18","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ccr.2006.03.027","article-title":"Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members","volume":"9","author":"Certo","year":"2006","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.hoc.2025.06.001_bib19","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1172\/JCI28281","article-title":"Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737","volume":"117","author":"Del Gaizo Moore","year":"2007","journal-title":"J Clin Investig"},{"issue":"17","key":"10.1016\/j.hoc.2025.06.001_bib20","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1182\/blood-2012-02-414060","article-title":"Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia","volume":"120","author":"Davids","year":"2012","journal-title":"Blood"},{"issue":"34","key":"10.1016\/j.hoc.2025.06.001_bib21","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.20.00948","article-title":"Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study","volume":"38","author":"Kater","year":"2020","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2025.06.001_bib22","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/blood.2021015014","article-title":"Enduring undetectable MRD and updated outcomes in relapsed\/refractory CLL after fixed-duration venetoclax-rituximab","volume":"140","author":"Seymour","year":"2022","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.hoc.2025.06.001_bib23","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1182\/blood.2024024631","article-title":"Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study","volume":"144","author":"Al-Sawaf","year":"2024","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2025.06.001_bib24","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Al-Sawaf","year":"2020","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.hoc.2025.06.001_bib25","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-line venetoclax combinations in chronic lymphocytic leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N Engl J Med"},{"issue":"30","key":"10.1016\/j.hoc.2025.06.001_bib26","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1200\/JCO.19.00894","article-title":"Ibrutinib plus venetoclax in relapsed\/refractory chronic lymphocytic leukemia: the CLARITY study","volume":"37","author":"Hillmen","year":"2019","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2025.06.001_bib27","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1001\/jamaoncol.2021.1649","article-title":"Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: a nonrandomized phase 2 trial","volume":"7","author":"Jain","year":"2021","journal-title":"JAMA Oncol"},{"issue":"34","key":"10.1016\/j.hoc.2025.06.001_bib28","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1200\/JCO.21.00807","article-title":"Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study","volume":"39","author":"Wierda","year":"2021","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2025.06.001_bib29","doi-asserted-by":"crossref","first-page":"e879","DOI":"10.1016\/S2352-3026(21)00307-0","article-title":"Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial","volume":"8","author":"Soumerai","year":"2021","journal-title":"Lancet Haematol"},{"issue":"7","key":"10.1016\/j.hoc.2025.06.001_bib30","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1200\/JCO-24-02503","article-title":"Phase II study of acalabrutinib, venetoclax, and obinutuzumab in a treatment-naive chronic lymphocytic leukemia population enriched for high-risk disease","volume":"43","author":"Davids","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2025.06.001_bib31","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1038\/s41467-019-10363-1","article-title":"Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations","volume":"10","author":"Birkinshaw","year":"2019","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.hoc.2025.06.001_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24065802","article-title":"Landscape of BCL2 resistance mutations in a real-world cohort of patients with relapsed\/refractory chronic lymphocytic leukemia treated with venetoclax","volume":"24","author":"Kotmayer","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"20","key":"10.1016\/j.hoc.2025.06.001_bib33","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2022016040","article-title":"Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy","volume":"140","author":"Thijssen","year":"2022","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.hoc.2025.06.001_bib34","doi-asserted-by":"crossref","first-page":"5455","DOI":"10.1158\/1078-0432.CCR-21-4037","article-title":"Lisaftoclax (APG-2575) is a novel BCL-2 inhibitor with robust antitumor activity in preclinical models of hematologic malignancy","volume":"28","author":"Deng","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"18","key":"10.1016\/j.hoc.2025.06.001_bib35","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1182\/blood.2023019706","article-title":"Sonrotoclax overcomes BCL2 G101V mutation-induced venetoclax resistance in preclinical models of hematologic malignancy","volume":"143","author":"Liu","year":"2024","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.hoc.2025.06.001_bib36","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1182\/blood.2021014304","article-title":"Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies","volume":"140","author":"Thomalla","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2025.06.001_bib37","volume":"138","author":"Seymour","year":"2021","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2025.06.001_bib38","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2021108690","article-title":"BCL-2-family protein tBID can act as a BAX-like effector of apoptosis","volume":"41","author":"Flores-Romero","year":"2022","journal-title":"EMBO J"},{"issue":"8","key":"10.1016\/j.hoc.2025.06.001_bib39","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1182\/blood.2021012775","article-title":"Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL","volume":"139","author":"Blombery","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2025.06.001_bib40","doi-asserted-by":"crossref","first-page":"4613","DOI":"10.1182\/blood-2024-208727","article-title":"Clonal hematopoiesis in patients with chronic lymphocytic leukemia treated with fixed-duration venetoclax-obinutuzumab or chlorambucil-obinutuzumab: insights from the randomized CLL14 trial","volume":"144","author":"Al-Sawaf","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2025.06.001_bib41","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41467-018-03170-7","article-title":"Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia","volume":"9","author":"Herling","year":"2018","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.hoc.2025.06.001_bib42","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1182\/blood.2020005734","article-title":"Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1","volume":"137","author":"Kohlhaas","year":"2021","journal-title":"Blood"},{"issue":"6629","key":"10.1016\/j.hoc.2025.06.001_bib43","doi-asserted-by":"crossref","DOI":"10.1126\/science.abj7412","article-title":"BTG1 mutation yields supercompetitive B cells primed for malignant transformation","volume":"379","author":"Mlynarczyk","year":"2023","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.hoc.2025.06.001_bib44","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-020-03144-y","article-title":"Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance","volume":"11","author":"Kapoor","year":"2020","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.hoc.2025.06.001_bib45","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.525","article-title":"MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K\/AKT\/mTOR activation in lymphoid malignancies","volume":"6","author":"Choudhary","year":"2015","journal-title":"Cell Death Dis"},{"issue":"25","key":"10.1016\/j.hoc.2025.06.001_bib46","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1182\/blood.2019004326","article-title":"Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL","volume":"136","author":"Haselager","year":"2020","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2025.06.001_bib47","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/leu.2014.320","article-title":"Hypoxia-induced p38 MAPK activation reduces Mcl-1 expression and facilitates sensitivity towards BH3 mimetics in chronic lymphocytic leukemia","volume":"29","author":"Huelsemann","year":"2015","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.hoc.2025.06.001_bib48","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.molcel.2006.02.009","article-title":"Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1","volume":"21","author":"Maurer","year":"2006","journal-title":"Mol Cell"},{"issue":"22","key":"10.1016\/j.hoc.2025.06.001_bib49","doi-asserted-by":"crossref","DOI":"10.1172\/JCI170169","article-title":"Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies","volume":"133","author":"Chong","year":"2023","journal-title":"J Clin Investig"},{"issue":"4","key":"10.1016\/j.hoc.2025.06.001_bib50","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccell.2019.08.005","article-title":"Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies","volume":"36","author":"Guieze","year":"2019","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.hoc.2025.06.001_bib51","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1182\/blood.2022016600","article-title":"Genetic events associated with venetoclax resistance in CLL identified by whole-exome sequencing of patient samples","volume":"142","author":"Khalsa","year":"2023","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2025.06.001_bib52","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1038\/s41418-020-00692-w","article-title":"Regulation of Bcl-XL by non-canonical NF-kappaB in the context of CD40-induced drug resistance in CLL","volume":"28","author":"Haselager","year":"2021","journal-title":"Cell Death Differ"},{"issue":"36","key":"10.1016\/j.hoc.2025.06.001_bib53","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1038\/onc.2010.248","article-title":"Dichotomy in NF-kappaB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40\/TLR9 triggering","volume":"29","author":"Tromp","year":"2010","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.hoc.2025.06.001_bib54","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1182\/blood-2006-05-021683","article-title":"Differential Noxa\/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity","volume":"109","author":"Smit","year":"2007","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.hoc.2025.06.001_bib55","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1182\/blood.2024024341","article-title":"Venetoclax dose escalation rapidly activates a BAFF\/BCL-2 survival axis in chronic lymphocytic leukemia","volume":"144","author":"Luo","year":"2024","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2025.06.001_bib56","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1007\/s10147-024-02611-2","article-title":"Current status of BAFF targeting immunotherapy in B-cell neoplasm","volume":"29","author":"Tagami","year":"2024","journal-title":"Int J Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2025.06.001_bib57","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/1878-0261.13364","article-title":"JAK-STAT signalling shapes the NF-kappaB response in CLL towards venetoclax sensitivity or resistance via Bcl-XL","volume":"17","author":"Haselager","year":"2023","journal-title":"Mol Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2025.06.001_bib58","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/10428194.2022.2131408","article-title":"IFN-gamma enhances CLL cell resistance to ABT-199 by regulating MCL-1 and BCL-2 expression via the JAK-STAT3 signaling pathway","volume":"64","author":"Shao","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.hoc.2025.06.001_bib59","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/s41571-018-0037-8","article-title":"Evolution of CLL treatment - from chemoimmunotherapy to targeted and individualized therapy","volume":"15","author":"Burger","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"10.1016\/j.hoc.2025.06.001_bib60","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047519","article-title":"Hypoxia-induced modulation of apoptosis and BCL-2 family proteins in different cancer cell types","volume":"7","author":"Sermeus","year":"2012","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.hoc.2025.06.001_bib61","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1182\/bloodadvances.2023012221","article-title":"BTK inhibitors in CLL: second-generation drugs and beyond","volume":"8","author":"Tam","year":"2024","journal-title":"Blood Adv"},{"issue":"22","key":"10.1016\/j.hoc.2025.06.001_bib62","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","article-title":"Ibrutinib and venetoclax for first-line treatment of CLL","volume":"380","author":"Jain","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.hoc.2025.06.001_bib63","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/leu.2017.32","article-title":"Bruton\u2019s tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia","volume":"31","author":"Deng","year":"2017","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.hoc.2025.06.001_bib64","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25063234","article-title":"Targeting BTK in B cell malignancies: from mode of action to resistance mechanisms","volume":"25","author":"Mouhssine","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"25","key":"10.1016\/j.hoc.2025.06.001_bib65","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1182\/blood-2015-10-675009","article-title":"BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199","volume":"127","author":"Bojarczuk","year":"2016","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hoc.2025.06.001_bib66","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1182\/blood-2015-12-687814","article-title":"High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells","volume":"128","author":"Oppermann","year":"2016","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.hoc.2025.06.001_bib67","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1182\/blood-2012-05-431783","article-title":"B-cell receptor triggers drug sensitivity of primary CLL cells by controlling glucosylation of ceramides","volume":"120","author":"Schwamb","year":"2012","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.hoc.2025.06.001_bib68","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.1158\/1078-0432.CCR-24-0967","article-title":"PI3K inhibitors in hematology: when one door closes","volume":"30","author":"Skanland","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.hoc.2025.06.001_bib69","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1080\/10428194.2021.1948038","article-title":"Idelalisib immune-related toxicity is associated with improved treatment response","volume":"62","author":"Wagner-Johnston","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.hoc.2025.06.001_bib70","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/s41467-023-37648-w","article-title":"Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia","volume":"14","author":"Al-Sawaf","year":"2023","journal-title":"Nat Commun"},{"issue":"13","key":"10.1016\/j.hoc.2025.06.001_bib71","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1158\/1078-0432.CCR-22-3321","article-title":"Novel BCL-2 inhibitor lisaftoclax in relapsed or refractory chronic lymphocytic leukemia and other hematologic malignancies: first-in-human open-label trial","volume":"29","author":"Ailawadhi","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2025.06.001_bib72","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-179541","volume":"142","author":"Tam","year":"2023","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hoc.2025.06.001_bib73","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14071715","article-title":"Recent advances in CAR T-cell therapy for patients with chronic lymphocytic leukemia","volume":"14","author":"Heyman","year":"2022","journal-title":"Cancers"},{"issue":"15","key":"10.1016\/j.hoc.2025.06.001_bib74","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1182\/bloodadvances.2022009517","article-title":"Cytotoxicity of the CD3xCD20 bispecific antibody amporitana in CLL is increased by concurrent BTK or BCL-2 targeting","volume":"7","author":"Mhibik","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.hoc.2025.06.001_bib75","doi-asserted-by":"crossref","first-page":"S350","DOI":"10.1016\/S2152-2650(24)01274-6","article-title":"Epcoritamab induces deep responses in patients with Richter transformation (RT): primary results from the EPCORE CLL-1 trial","volume":"24","author":"Kater","year":"2024","journal-title":"Cl Lymph Myelom Leuk"},{"issue":"1","key":"10.1016\/j.hoc.2025.06.001_bib76","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41591-023-02722-9","article-title":"Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial","volume":"30","author":"Al-Sawaf","year":"2024","journal-title":"Nat Med"},{"issue":"26","key":"10.1016\/j.hoc.2025.06.001_bib77","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2017-02-765685","article-title":"Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL","volume":"129","author":"Ding","year":"2017","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.hoc.2025.06.001_bib78","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.hoc.2025.06.001_bib79","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"Bekes","year":"2022","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.hoc.2025.06.001_bib80","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41392-025-02176-0","article-title":"The BCL2 family: from apoptosis mechanisms to new advances in targeted therapy","volume":"10","author":"Vogler","year":"2025","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"10.1016\/j.hoc.2025.06.001_bib81","doi-asserted-by":"crossref","DOI":"10.3390\/cells13121041","article-title":"Lysosome-disrupting agents in combination with venetoclax increase apoptotic response in primary chronic lymphocytic leukemia (CLL) cells mediated by lysosomal cathepsin D release and inhibition of autophagy","volume":"13","author":"Manivannan","year":"2024","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.hoc.2025.06.001_bib82","first-page":"151","article-title":"Electron transport chain and mTOR inhibition synergistically decrease CD40 signaling and counteract venetoclax resistance in chronic lymphocytic leukemia","volume":"109","author":"Chen","year":"2024","journal-title":"Haematologica"},{"issue":"6059","key":"10.1016\/j.hoc.2025.06.001_bib83","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1126\/science.1206727","article-title":"Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy","volume":"334","author":"Ni","year":"2011","journal-title":"Science"},{"issue":"19","key":"10.1016\/j.hoc.2025.06.001_bib84","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1158\/1078-0432.CCR-22-0433","article-title":"Circulating tumor DNA-based MRD assessment in patients with CLL treated with obinutuzumab, acalabrutinib, and venetoclax","volume":"28","author":"Furstenau","year":"2022","journal-title":"Clin Cancer Res"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858825000851?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858825000851?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:56Z","timestamp":1778544056000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858825000851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":84,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0889858825000851"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2025.06.001","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Understanding and Targeting BCL2-inhibitor Resistance in Chronic Lymphocytic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2025.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}